Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2023

10-09-2023 | ASO Author Reflections

ASO Author Reflections: Proposal of Tumor Size as an Index for Biologic Factor of Resectability Status of Pancreatic Ductal Adenocarcinoma

Authors: Yoichi Miyata, MD, PhD, Yoji Kishi, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2023

Login to get access

Excerpt

The treatment strategy for pancreatic ductal adenocarcinoma (PDAC) has been decided according to resectability status.1,2 Tumor size (TS) is a simple but definite prognostic factor and has been employed to determine the T factor of the TNM staging system.3 Resectability status, however, defined on the basis of only anatomic tumor extension, especially in relation with the surrounding major vessels and TS, is not accounted for. There is a concern regarding whether all patients with the same resectability status should be treated uniformly irrespective of TS. …
Literature
1.
2.
Murakami Y, Satoi S, Sho M, et al. National comprehensive cancer network resectability status for pancreatic carcinoma predicts overall survival. World J Surg. 2015;39:2306–14.CrossRefPubMed
3.
Brierley JD, Gospodarowicz MK, Wittekind C. International Union against Cancer (UICC). TNM Classification of Malignant Tumors. New York: Wiley; 2017.
4.
5.
Isaji S, Mizuno S, Widsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.CrossRefPubMed
Metadata
Title
ASO Author Reflections: Proposal of Tumor Size as an Index for Biologic Factor of Resectability Status of Pancreatic Ductal Adenocarcinoma
Authors
Yoichi Miyata, MD, PhD
Yoji Kishi, MD, PhD
Publication date
10-09-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14261-1

Other articles of this Issue 13/2023

Annals of Surgical Oncology 13/2023 Go to the issue

Breast Oncology

Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes

Pancreatic Tumors

Bovine Pericardial Graft for Portomesenteric Reconstruction During Robotic Pancreatoduodenectomy

Colorectal Cancer

Lymph Node Metastases and Associated Recurrence-Free Survival in Microsatellite Stable and Unstable Colon Cancer

Hepatobiliary Tumors

The Effect of Histopathological Growth Patterns of Colorectal Liver Metastases on the Survival Benefit of Adjuvant Hepatic Arterial Infusion Pump Chemotherapy

ASO Visual Abstract

ASO Visual Abstract: Evaluation of Content Quality for Patients Searching YouTube for Videos on Cytoreductive Surgery and Hyperthermic Intraperitoneal Peritoneal Chemotherapy

ASO Visual Abstract

ASO Visual Abstract: Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy